These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
121 related articles for article (PubMed ID: 6739896)
21. [Immunological investigation of brain tumor patients (author's transl)]. Shimizu T; Kito K; Yamazaki N; Kubo O; Kitamura K Neurol Med Chir (Tokyo); 1976 Jul; 16(4 pt 2):337-47. PubMed ID: 62314 [No Abstract] [Full Text] [Related]
22. [Autosensitization of neurosurgical cases by normal brain tissue antigens (author's transl)]. Oda Y; Tokuriki Y; Takeuchi J; Handa H No Shinkei Geka; 1979 Oct; 7(10):953-9. PubMed ID: 392328 [TBL] [Abstract][Full Text] [Related]
23. Serologic analysis of nitrosourea-induced rat gliomas. Pfreundschuh M; Cravioto H; Hochwald G; Ransohoff J J Natl Cancer Inst; 1982 Mar; 68(3):501-5. PubMed ID: 6950179 [TBL] [Abstract][Full Text] [Related]
24. Carcinoembryonic antigen in patients with intracranial tumors. Suzuki Y; Tanaka R J Neurosurg; 1980 Sep; 53(3):355-60. PubMed ID: 7420150 [TBL] [Abstract][Full Text] [Related]
25. [Frequency and significance of lymphoplasmocyte infiltration in human gliomas (author's transl)]. Schiffer D; Croveri G; Pautasso C Tumori; 1974; 60(3):177-84. PubMed ID: 4372756 [No Abstract] [Full Text] [Related]
26. Autoantibodies to the inhibitor of apoptosis protein survivin in patients with brain tumors. Söling A; Plugge EM; Schmitz M; Weigle B; Jacob R; Illert J; Holzhausen HJ; Rainov NG Int J Oncol; 2007 Jan; 30(1):123-8. PubMed ID: 17143520 [TBL] [Abstract][Full Text] [Related]
27. Tumor markers of the central nervous system. Birkmayer GD Cancer Detect Prev; 1981; 4(1-4):231-8. PubMed ID: 7349780 [TBL] [Abstract][Full Text] [Related]
28. [Immunology of brain tumors: the glial carcino-fetal antigen]. Trouillas P Ann Inst Pasteur (Paris); 1972 Apr; 122(4):819-28. PubMed ID: 4340548 [No Abstract] [Full Text] [Related]
29. Tumor specific fluorescent and complement-dependent cytotoxic antibodies in the serum of rats with chemically induced brain gliomas. Stavrou D; Anzil AP; Elling H Acta Neuropathol; 1978 Aug; 43(1-2):111-7. PubMed ID: 676675 [TBL] [Abstract][Full Text] [Related]
31. [Value of immunologic studies in malignant tumors of the human brain]. Romodanov AP; Lisianyĭ NI; Prikhodchenko IA Zh Vopr Neirokhir Im N N Burdenko; 1983; (3):56-9. PubMed ID: 6310917 [No Abstract] [Full Text] [Related]
34. Serum immunoglobulins in brain tumours. Manjula S; Aroor AR; Raja A; Rao SN; Rao A Acta Neurochir (Wien); 1992; 115(3-4):103-5. PubMed ID: 1605076 [TBL] [Abstract][Full Text] [Related]
35. Cell- and peptide-based immunotherapeutic approaches for glioma. Yamanaka R Trends Mol Med; 2008 May; 14(5):228-35. PubMed ID: 18403264 [TBL] [Abstract][Full Text] [Related]
36. Tumor markers of the central nervous system: biological basis and clinical relevance. Birkmayer GD Cancer Detect Prev; 1983; 6(1-2):317-24. PubMed ID: 6883389 [TBL] [Abstract][Full Text] [Related]
37. [Soluble class HLA antigens in serum of patients with brain tumors]. Turowski G; Gościński I; Gieracka D; Kedzierska A; Pawłowska E; Danilewicz B Pol Merkur Lekarski; 1996 Dec; 1(6):410-1. PubMed ID: 9273234 [TBL] [Abstract][Full Text] [Related]
38. Relevance for neurobiology and neurooncology of antigens of malignant gliomas as defined by monoclonal antibodies. Vrionis FD; Wikstrand CJ; Bigner DD Ann N Y Acad Sci; 1988; 540():64-77. PubMed ID: 2462837 [No Abstract] [Full Text] [Related]
39. [Malignant central nervous system tumors are susceptible to specific antibodies]. Blizniukov OP; Kozmin LD; Oliushin VE; Ostreĭko OV; Filatov MV Vopr Onkol; 2001; 47(1):49-51. PubMed ID: 11317535 [TBL] [Abstract][Full Text] [Related]